Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

Cansu Cimen Bozkus; Nina Bhardwaj

doi:10.1016/j.ccell.2021.08.003

Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

Cancer Cell. 2021 Sep 13;39(9):1187-1189. doi: 10.1016/j.ccell.2021.08.003. Epub 2021 Sep 2.

Authors

Cansu Cimen Bozkus¹, Nina Bhardwaj²

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: nina.bhardwaj@mssm.edu.

PMID: 34478641
DOI: 10.1016/j.ccell.2021.08.003

Abstract

Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.

Publication types

Comment

MeSH terms

Biomarkers, Tumor
Humans
Immunity
Neoplasms* / drug therapy
Organoids
Programmed Cell Death 1 Receptor*

Substances

Biomarkers, Tumor
Programmed Cell Death 1 Receptor